Suppression of neural activity of bronchial irritant receptors by surface‐active phospholipid in comparison with topical drugs commonly prescribed for asthma
- 1 September 2000
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 30 (9), 1266-1274
- https://doi.org/10.1046/j.1365-2222.2000.00850.x
Abstract
Much indirect evidence has been put forward previously in support of the concept that surface-active phospholipid (SAPL) normally masks irritant receptors in the lungs and upper respiratory tract; but this physical barrier is deficient in asthmatics, imparting hyperresponsiveness of the bronchoconstrictor reflex. To determine whether exogenous SAPL applied to bronchial mucosa reduces the sensitivity of irritant receptors to a standard challenge used clinically to diagnose asthma and to compare the effects with those of corticosteroids and β-stimulation. Nerve fibres in the vagi were monitored to record action potentials from irritant receptors identified in the upper airways of rat lungs in response to a methacholine challenge. SAPL in the form of dipalmitoyl phosphatidylcholine (PC) and phosphatidylglycerol (PG) — 7 : 3 PC:PG — was applied as a fine dry powder to enhance surface activity and, hence, chemisorption to epithelium. Comparison was also made with clinical doses of i.v. hydrocortisone and instilled salbutamol together with liquid or solid controls, as appropriate. Neural activity of irritant receptors was found to be significantly (P = 0.0018) decreased by topical SAPL by 35.8% in response to a methacholine challenge in contrast to an increase of 11.2% in response to a solid (lactose) control. Instilled salbutamol and i.v. hydrocortisone also decreased responses to the same challenge by 43.4% and 14.7%, respectively, in contrast to a liquid (saline) control which increased by 24.5%. Surface-active phospholipid has an appreciable effect upon irritant receptors in rat airways, reducing neural response to a methacholine challenge by an amount comparable to that of Salbutamol. These results support the concept of SAPL masking bronchial irritant receptors and warrant placebo-controlled clinical trials of this dry powder as a means of controlling asthma without the side-effects of current medication. Other possible roles discussed for the SAPL epithelial barrier include the exclusion of viruses and allergens.Keywords
This publication has 24 references indexed in Scilit:
- "Dewatering" of the lungs at birth CommentaryArchives of Disease in Childhood: Fetal & Neonatal, 1998
- The link between the nose and lung, perennial rhinitis and asthma—is it the same disease?Allergy, 1997
- Gastric surfactant and the hydrophobic mucosal barrier.Gut, 1996
- Asthma: is there an airway receptor barrier?Thorax, 1996
- β-adrenergic priming of rats in vivo modulates the effect of β-agonist in vitro on surfactant phospholipid metabolism of isolated lungsEuropean Journal of Clinical Investigation, 1994
- In vitro lymphocyte functions in the presence of bovine surfactant and its phospholipid fractionsjpme, 1992
- Surfactant-like material on the chemoreceptorial surface of the frog's taste organ: An ultrastructural and electron spectroscopic imaging studyJournal of Structural Biology, 1991
- Corticosteroid pharmacokinetics in asthmaThe Lancet, 1990
- The contact angle induced by DPL at pulmonary epithelial surfacesRespiration Physiology, 1979
- Reproducibility and comparison of responses to inhaled histamine and methacholine.Thorax, 1978